<DOC>
	<DOCNO>NCT01325207</DOCNO>
	<brief_summary>The drug study Trastuzumab , medicine use slow stop growth cancerous tumor HER-2 positive . Patients ask participate study diagnose tumor cell spinal fluid . This study investigate safety effect drug give directly spinal fluid . Phase I/II Dose Escalation Trial Assess Safety Intrathecal Trastuzumab Treatment Leptomeningeal Metastases HER2 Positive Breast Cancer The purpose research study determine safe dose drug Trastuzumab determine effective treatment .</brief_summary>
	<brief_title>Intrathecal Trastuzumab Leptomeningeal Metastases HER2+ Breast Cancer</brief_title>
	<detailed_description>Phase I : Patients treat cohort 3-6 base standard phase I dose escalation parameter require 0/3 1/6 patient per cohort DLT dose escalation . Dosing follow : Cohort 1-10 mg IT , cohort 2-20 mg IT , cohort 3-30 mg IT cohort 4-40 mg IT . Patients treat twice week 4 week , week 4 week , every 2 week . Toxicity DLT assess first 4 week treatment . Phase II : Patients treat MTD maximal define dose . Patients treat twice week 4 week , week 4 week , every 2 week .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>ELIGIBILITY CRITERIA HER2 positive ( IHC 3+ and/or FISH positive ) breast cancer patient leptomeningeal metastasis MRI CSF ( MRI negative ) . Review perform case review Northwestern confirmation , preclude patient enter trial ( pathology report sufficient registration ) . Patients concomitant brain metastasis long require active treatment treat . Patients leptomeningeal disease ependymomas , glioma , medulloblastoma eligible phase I Life expectancy &gt; 8 week Normal renal ( creatinine &lt; 1.5 ULN ) , liver ( bilirubin &lt; 1.5 x ULN , transaminases &lt; 3.0 x ULN , except know hepatic metastasis , wherein may &lt; 5 x ULN ) blood count ( WBC &gt; 3.0 , Neutrophils &gt; 1500 , platelets &gt; 100 000 , Hemoglobin &gt; 10 ) . LVEF &gt; 50 % KPS &gt; 50 Age &gt; 18 year Can systemic agent ( chemotherapy ) CNS penetration unless develop leptomeningeal metastasis agent ( ) control systemic disease . May continue IV trastuzumab , lapatinib hormonal agent control systemic disease develop LM therapy . Patients require systemic chemotherapy eligible able start treatment first assessment image cytology . Patients may need CSF flow study discretion treat principal investigator . If spinal block see CSF flow study MRI , need local RT prior treatment . Concurrent radiation allow . Patients &gt; 2 week RT treatment effect treatment resolve No limit prior systemic IT therapies . CSF sample document LM document MRI . Must willing Ommaya reservoir place . NO history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) unless complete remission therapy disease minimum 3 year . Significant medical psychiatric illness would interfere compliance ability tolerate treatment outline protocol . Women childbearing potential sexually active male must commit use effective contraception study . Women may pregnant breastfeeding . Ability sign inform consent ; sign family member health care proxy . Informed consent must do prior registration study . All patient must give sign , informed consent prior registration study . No known hypersensitivity trial medication Note : The eligibility criterion list interpret literally waive . Any deviation inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>